累积癌灶位置数是预测主动监测结局的新指标:一项多中心研究
CCLO高危组协议性终止、Gleason升级及根治性前列腺切除标本不良发现的风险均显著更高,且预测效能优于确认性活检阳性针数。
要点
- CCLO由诊断性与确认性活检中癌阳性位置数累加获得,区别于阳性针数。
- CCLO高危组协议性终止风险显著升高(HR 12.15,95%CI 6.18-23.9)。
- CCLO预测协议性终止的AUC为0.734,优于确认性活检阳性针数的0.682。
核心结论
- CCLO与活检阳性针数不同,较高的CCLO可预测AS结局,可能有助于筛选适合AS的患者。
研究设计与样本
- 回顾性研究队列由三个前瞻性AS队列组成:赫尔辛基大学医院n=316、欧洲肿瘤研究所n=204、明斯特大学n=89。
- CCLO通过累加诊断性与确认性活检中组织学癌阳性位置总数获得。
主要发现
- Kaplan-Meier分析中,CCLO高危组所有结局(协议性终止、Gleason升级、根治性前列腺切除标本不良发现)的无事件生存期均显著更短(所有p<0.002)。
- 多变量Cox回归中,CCLO高危组协议性终止风险显著更高(HR 12.15,95%CI 6.18-23.9;p<0.001)。
- CCLO高危组Gleason升级风险显著更高(HR 6.01,95%CI 2.16-16.8;p=0.002)。
- CCLO高危组根治性前列腺切除标本不良发现风险显著更高(HR 9.144,95%CI 2.27-36.9;p=0.006)。
- ROC分析中,CCLO预测协议性终止的AUC为0.734 vs 确认性活检阳性针数0.682,预测Gleason升级为0.655 vs 0.576,预测根治性前列腺切除标本不良发现为0.662 vs 0.561,决策曲线分析支持其附加价值。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Active surveillance (AS) of prostate cancer (PC) has increased in popularity to address overtreatment. OBJECTIVE: To determine whether a novel metric, cumulative cancer locations (CCLO), can predict AS outcomes in a group of AS patients with low and very low risk. DESIGN, SETTING, AND PARTICIPANTS: CCLO is obtained by summing the total number of histological cancer-positive locations in both diagnostic and confirmatory biopsies (Bx). The retrospective study cohort comprised three prospective AS cohorts (Helsinki University Hospital: n=316; European Institute of Oncology: n=204; and University of Münster: n=89). OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS: We analyzed whether risk stratification based on CCLO predicts different AS outcomes: protocol-based discontinuation (PBD), Gleason upgrading (GU) during AS, and adverse findings in radical prostatectomy (RP) specimens. RESULTS: In Kaplan Meier analyses, patients in the CCLO high-risk group experienced significantly shorter event-free survival for all outcomes (PBD, GU, and adverse RP findings; all p<0.002). In multivariable Cox regression analysis, patients in the CCLO high-risk group had a significantly higher risk of experiencing PBD (hazard ratio [HR] 12.15, 95% confidence interval [CI] 6.18-23.9; p<0.001), GU (HR 6.01, 95% CI 2.16-16.8; p=0.002), and adverse RP findings (HR 9.144, 95% CI 2.27-36.9; p=0.006). In receiver operating characteristic analyses, the area under the curve for CCLO outperformed the number of cancer-positive Bxs in confirmatory Bx in predicting PBD (0.734 vs 0.682), GU (0.655 vs 0.576) and adverse RP findings (0.662 vs 0.561) and the added value was supported by decision curve analysis. CONCLUSIONS: CCLO is distinct from the number of positive Bx cores. Higher CCLO predicts AS outcomes and may aid in selection of patients for AS. PATIENT SUMMARY: For patients on active surveillance for prostate cancer, the cumulative number of cancer-positive locations in diagnostic and confirmatory biopsies is a predictor of active surveillance outcomes.
引用
- Erickson AM, Luzzago S, Semjonow A, et al. Cumulative Cancer Locations is a Novel Metric for Predicting Active Surveillance Outcomes: A Multicenter Study. Eur Urol Oncol. 2018. PMID: 31100247. doi:10.1016/j.euo.2018.04.006
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。